How confident are you in your country’s healthcare system? That was the central issue for this month’s PME cover feature, which focused on a global study of healthcare perceptions and offered some useful insights into how people think and feel when faced with healthcare decisions.
We also looked at the global scourge that is the problem of counterfeit medicines and hear what the industry is doing to help tackle the problem.
And there’s a preview of the options open to the EMA when it issues its forthcoming drug shortage report and a look at the measures already taken by the likes of France and Portugal.
In July/August’s PME we looked at what the Brexit vote to leave the European Union will mean for the European pharmaceutical industry. With clarity on the issue still in rather short supply, September’s issue concentrated on the implications of Brexit for the UK biopharma industry.
Meanwhile, we look at business models, but Professor Brian D Smith warns that charting choosing the right one from the dozens available is fraught with hidden and not-so-hidden dangers.
The issue also came with our latest European Market Access supplement. This time around we look at the direction of travel in France and Germany, and give an overview of the UK’s new-look Cancer Drugs Fund.
The issue in numbers:
If health spending continues to increase at current rates it will hit an unsustainable 50% of GDP for most OECD countries by 2100.
An Interpol-led investigation earlier this year closed 4,932 illegal online pharmacies and seized 12.2 million counterfeit drugs. But 80% of people are unaware that most online pharmacies operate illegally.
The number of people models available to pharmaceutical companies? 26.
Some 49% of people see themselves as fully responsible for their healthcare and 59% of people have consulted health websites in the past year. But only 7% say the internet is their preferred source of information.